Approved HIV Drugs
Approved HIV Drugs
HIV Integrase Inhibitor Elvitegravir Approved in European Union
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Gilead Sciences
The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.
U.S. HIV Treatment Guidelines Expand Integrase Inhibitor Recommendations
- Details
- Category: Approved HIV Drugs
- Published on Monday, 04 November 2013 00:00
- Written by DHHS
The U.S. Department of Health and Human Services antiretroviral therapy guidelines panel has updated its list of preferred regimens for first-line treatment to include 2 additional HIV integrase inhibitors, elvitegravir (part of the Stribild single-tablet regimen) and dolutegravir (Tivicay).
EACS 2013: Dolutegravir Matches or Beats Other Antiretrovirals for First-line HIV Treatment
- Details
- Category: Approved HIV Drugs
- Published on Friday, 25 October 2013 00:00
- Written by Liz Highleyman
The recently approved HIV integrase inhibitor dolutegravir (Tivicay) provides at least equivalent antiviral efficacy and better tolerability compared with approved antiretroviral drugs for treatment-naive people, according to data reported at the 14th European AIDS Conference last week in Brussels and in the current edition of Lancet Infectious Diseases.
EACS 2013: Once-daily Raltegravir Effective as Maintenance Therapy; New Formulation in Development
- Details
- Category: HIV Treatment
- Published on Wednesday, 30 October 2013 00:00
- Written by Liz Highleyman
Almost all HIV positive people with undetectable viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers reported at the 14thEuropean AIDS Conference this month in Brussels. In an effort to facilitate once-daily dosing, Merck is working on a new tablet that appears less affected by food than the current formulation.
EACS 2013: Dual Therapy with Kaletra + Lamivudine Works Well Regardless of Viral Load
- Details
- Category: Approved HIV Drugs
- Published on Saturday, 19 October 2013 00:00
- Written by Liz Highleyman
A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus lamivudine (3TC or Epivir) as first-line therapy produced good virological suppression regardless of baseline viral load and was well-tolerated in the multinational GARDEL study, according to a late-breaking report at the 14thEuropean AIDS Conference this week in Brussels.
Web Design and Development by